Young-Ho Jung

Young-Ho Jung

Auto-generated profile, based on publicly available information

Young-Ho Jung

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Plant Physiology and Biochemistry
Verified
Journal Article
Closed access
YJYoung-Ho Jung
Young-Ho Jung
Joohee LeeJoohee Lee
Joohee Lee
GAGanesh Kumar Agrawal
Ganesh Kumar Agrawal
RRRandeep Rakwal
Randeep Rakwal
JKJung-A Kim
Jung-A Kim
NJNam-Soo Jwa
Nam-Soo Jwa

23 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
YZYan Zhu
Yan Zhu
DZDengyong Zhang
Dengyong Zhang
PSPooja Shukla
Pooja Shukla
YJYoung-Ho Jung
Young-Ho Jung
PMPrit Benny Malgulwar
Prit Benny Malgulwar
LKLawrence Kwong
Lawrence Kwong
Patients with cholangiocarcinoma have poor clinical outcomes due to late diagnoses, poor prognoses, and limited treatment strategies. To identify drug combinations for this disease, we have conducted a genome-wide CRISPR screen anchored on the bromodomain and extraterminal domain (BET) PROTAC degrader ARV825, from which we identified anticancer synergy when combined with genetic ablation of members of the mTOR pathway. This combination effect was validated using multiple pharmacological BET and mTOR inhibitors, accompanied by increased levels of apoptosis and cell cycle arrest. In a xenograft model, combined BET degradation and mTOR inhibition induced tumor regression. Mechanistically, the 2 inhibitor classes converged on H3K27ac-marked epigenetic suppression of the serine glycine one carbon (SGOC) metabolism pathway, including the key enzymes PHGDH and PSAT1. Knockdown of PSAT1 was sufficient to replicate synergy with single-agent inhibition of either BET or mTOR. Our results tie together epigenetic regulation, metabolism, and apoptosis induction as key therapeutic targets for further exploration in this underserved disease.